Nasdaq listed company BioNexus Gene Lab announces adoption of Ethereum financial reserve strategy

According to Globenewswire, BioNexus Gene Lab Corp. (NASDAQ: BGLC), a technology company dedicated to technological innovation and healthcare, announced that its board of directors has officially approved the company's new Ethereum focused financial strategy. This decision marks BGLC as the first Nasdaq listed company to exclusively prioritize Ethereum as a strategic financial asset, and echoes the recent announcement that Ethereum has been included in the US "Cryptocurrency Strategic Reserve". At the same time, BGLC has released an Ethereum strategy white paper, detailing the reasons behind the company's decisions and the broader significance of Ethereum as a financial infrastructure asset. The white paper delves into the adoption of Ethereum in institutions, staking capabilities, and upcoming protocol upgrades, which solidify Ethereum's long-term value and practicality for businesses.